GlassScriptPhysician profile
Jesus Hernandez
NPI 1568462398
$1,467.28
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $610 · 2021: $81.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.82 | 2019-2021 | |
| Abbvie INC. | $298.29 | 2019-2021 | |
| Pfizer INC. | $189.89 | 2019-2020 | |
| Gilead Sciences, INC. | $119.40 | 2019-2020 | |
| Janssen Biotech, INC. | $84.24 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $77.38 | 2019-2020 | |
| Shire North American Group INC | $58.17 | 2019 | |
| Ironwood Pharmaceuticals, INC | $57.08 | 2020 | |
| Merck Sharp & Dohme LLC | $51.68 | 2020 | |
| Redhill Biopharma INC. | $40.13 | 2020 | |
| Daiichi Sankyo INC. | $36.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.87 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $28.59 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.90 | 2019 | |
| Ambu INC. | $22.04 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.55 | 2020 | |
| Ucb, INC. | $16.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.